OKT3 rescues leukemia engraftment. (A) Representative FACS plots showing predominant T-cell engraftment in BM and PB of control mice and predominant leukemia engraftment in the NSG mice that received OKT3 pretreated human B-ALL patient cells. (B) A similar analysis and result is shown for the NSGS BM and spleen (SPL) of mice that received human patient AML cells. (C) Latency of AML induced in NSGS mice by the MA9.3RAS cell line (left) or the AML1001 patient sample (right) was not altered by pretreatment of cells with OKT3.